The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

When people were randomised to receive either a placebo or Ozempic, they became biologically younger with the latter drug ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.